logo
Plus   Neg
Share
Email

Roche: FDA To Review BLA For Fixed-dose Combination Of Perjeta, Herceptin

Roche (RHHBY) said the US FDA has accepted the company's Biologics License Application for the fixed-dose combination of Perjeta and Herceptin with hyaluronidase, for the treatment of eligible patients with HER2-positive breast cancer. The FDA decision on the BLA is expected by 18 October 2020.

Levi Garraway, Chief Medical Officer and Head of Global Product Development, said: "Today's acceptance builds upon our commitment by potentially offering patients a faster way to administer Perjeta and Herceptin. We're working with the FDA to bring this treatment option to patients as quickly as possible."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill, Inc. is giving away 100,000 burritos to healthcare workers, who are at present fighting in the front line against coronavirus or Covid-19 pandemic. The food chain has asked healthcare teams to submit their application by Thursday, April 2, which is this year's National Burrito day. The offer is valid for a free preconfigured Burritos by the Box order of 25 burritos. The U.S. Food and Drug Administration has urged to withdraw Sanofi's heartburn drug Ranitidine as well as its generics from the market with immediate effect for possible contamination. The recall involves all prescription and over-the-counter or OTC ranitidine drugs, commonly known by the brand name Zantac. The recall includes generic products that contain ranitidine made by Novartis, Endo... Drugstore chain Walgreens and courier services provider Postmates said they have expanded on-demand delivery to more than 7,000 Walgreens stores nationwide. The companies expect the service will help capitalize on the rising need for home delivery amid the coronavirus pandemic. The expansion will enable consumers in cities across the country to get home delivery of health and wellness items.
Follow RTT
>